PROMIS NEUROSCIENCES ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

TORONTO, ON. and CAMBRIDGE, MA. – July 24, 2019 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,  today announced the voting results of the Corporation’s annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario, Canada (the “Meeting”).  MORE>>